Short answer
Zimmer Biomet (ZBH) filed its fiscal 2024 10-K annual report with the SEC on Feb 25, 2025. It reported revenue of $7.7B (+3.8% year over year) and net income of $904M.
FY2024 key financial metrics · XBRL
- Revenue
- $7.7B
- +3.8% YoY
- Net income
- $904M
- −11.7% YoY
- Operating margin
- 16.7%
- −0.5 pp YoY
- EPS (diluted)
- $4.43
- −9.2% YoY
- ROE
- 7.2%
- −1.0 pp YoY
- Operating cash flow
- $1.5B
- −5.2% YoY
Source: XBRL data from the Zimmer Biomet (ZBH) FY2024 10-K on SEC EDGAR. USD.
Zimmer Biomet FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Medical device design, manufacture, and distribution focused on orthopedic products
- No new products, services, or segments introduced or emphasized this year
- No strategic shifts or changed competitive positioning disclosed in this filing
- Code of ethics adopted specifically for CEO and senior financial officers, publicly available online
- Insider trading policy implemented for directors, senior management, and employees, filed as exhibit to this 10-K
Generated from the filing text; verify against the original. How to read a 10-K
Other Zimmer Biomet annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.